Sanofi (SNYN) - Total Assets
Based on the latest financial reports, Sanofi (SNYN) holds total assets worth MX$129.06 Billion MXN (≈ $7.43 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sanofi - Total Assets Trend (2013–2025)
This chart illustrates how Sanofi's total assets have evolved over time, based on quarterly financial data. Also see SNYN company net worth for the company's overall valuation and market capitalisation.
Sanofi - Asset Composition Analysis
Current Asset Composition (December 2025)
Sanofi's total assets of MX$129.06 Billion consist of 24.4% current assets and 75.6% non-current assets. Review Sanofi debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (MXN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 6.0% |
| Accounts Receivable | MX$8.41 Billion | 6.6% |
| Inventory | MX$10.21 Billion | 8.1% |
| Property, Plant & Equipment | MX$0.00 | 0.0% |
| Intangible Assets | MX$26.26 Billion | 20.7% |
| Goodwill | MX$41.30 Billion | 32.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Sanofi's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Sanofi (SNYN) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sanofi's current assets represent 24.4% of total assets in 2025, a decrease from 24.9% in 2013.
- Cash Position: Cash and equivalents constituted 6.0% of total assets in 2025, down from 8.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 51.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 32.6% of total assets.
Sanofi Competitors by Total Assets
Key competitors of Sanofi based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Roche Holding AG
SW:ROP
|
Switzerland | CHF100.70 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥1.60 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
Sanofi - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.99 | 1.27 | 1.55 |
| Quick Ratio | 0.64 | 0.94 | 1.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | MX$-408.00 Million | MX$7.96 Billion | MX$10.45 Billion |
Sanofi - Advanced Valuation Insights
This section examines the relationship between Sanofi's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.79 |
| Asset Growth Rate (YoY) | -4.5% |
| Total Assets | MX$126.81 Billion |
| Market Capitalization | $100.25 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sanofi's assets below their book value (0.79x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Sanofi's assets decreased by 4.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sanofi (2013–2025)
The table below shows the annual total assets of Sanofi from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | MX$126.81 Billion ≈ $7.30 Billion |
-4.51% |
| 2024-12-31 | MX$132.80 Billion ≈ $7.64 Billion |
+5.01% |
| 2023-12-31 | MX$126.46 Billion ≈ $7.28 Billion |
+1.51% |
| 2022-12-31 | MX$124.58 Billion ≈ $7.17 Billion |
+3.61% |
| 2021-12-31 | MX$120.24 Billion ≈ $6.92 Billion |
+4.99% |
| 2020-12-31 | MX$114.53 Billion ≈ $6.59 Billion |
+1.59% |
| 2019-12-31 | MX$112.74 Billion ≈ $6.49 Billion |
+1.19% |
| 2018-12-31 | MX$111.41 Billion ≈ $6.41 Billion |
+11.60% |
| 2017-12-31 | MX$99.83 Billion ≈ $5.75 Billion |
-4.63% |
| 2016-12-31 | MX$104.67 Billion ≈ $6.02 Billion |
+2.30% |
| 2015-12-31 | MX$102.32 Billion ≈ $5.89 Billion |
+5.06% |
| 2014-12-31 | MX$97.39 Billion ≈ $5.60 Billion |
+1.39% |
| 2013-12-31 | MX$96.06 Billion ≈ $5.53 Billion |
-- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, ty… Read more